News

The adjunct professor of human genetics at Emory University School of Medicine discussed how the Rett Syndrome Behavior Questionnaire has evolved into a versatile tool with a broader scope. [WATCH TIME: 10 minutes]

In a recent case-control study of 836 human serum samples, including 332 AQP4-IgG–positive and 504 negative samples, the novel immunodot assay showed a 99.4% sensitivity and a 99.2% specificity.

The associate professor at Washington University School of Medicine discussed the reasons for why some institutions have different risk benefit analyses for thrombolysis, and whether this causes challenges for the healthcare system. [WATCH TIME: 4 minutes]

In this small-scale Turkish-based substudy, stopping eciluzumab appeared to be associated with a “rebound” effect with a high risk of relapse in patients with NMOSD.

An expert neurology panel detailed some of the changes in therapeutic strategies and approaches to treating rare neuroimmune disorders, including the steps taken during the acute phase. [WATCH TIME: 6 minutes]

In a recent study on patients with narcolepsy type 1, those who used opioid drugs such as oxycodone and codeine were significantly associated with improved self-reported narcolepsy symptom severity.

The chief medical officer at ML Bio Solutions, an affiliate of BridgeBio, talked about the significant progress of investigational agent BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9. [WATCH TIME: 3 minutes]

A recent systematic review and meta-analysis showed that normal mean sleep latency in adults was 11.7 minutes using the earlier definition of sleep onset and 11.8 minutes using the later definition of sleep onset.

The presence of new asymptomatic MRI lesions among patients with NMOSD during the relapse-free period and at relapses was not associated with a shorter time to developing subsequent relapses.

Several experts in neuroimmune disorders discuss the mechanisms of action that underlie these disorders, and how the perception of their pathology has changed. [WATCH TIME: 7 minutes]

Findings from a recent exploratory study suggest that assessing daily functioning in a more sensitive way may identify Alzheimer disease before a patient develops more pronounced cognitive changes.

The professor of neurology at the NYU Grossman School of Medicine discussed the RECOVER-NEURO trial that is focused on improving cognitive dysfunction in patients with long COVID symptoms. [WATCH TIME: 5 minutes]

The director of the Pediatric Epilepsy Center at UCSF provided perspective on STK-001, a promising antisense oligonucleotide in development, and the shift in how Dravet syndrome is discussed and managed.

Patients treated for more than 28 days had a higher chance of status epilepticus cessation, but also a high risk of moderate to severe disability at discharge.

One meta-analysis featuring 8 studies showed that more than half of patients reported a 100% reduction in their generalized tonic-clonic seizures or tonic-clonic seizures.

A group of panelists discussed the history of the Siegel Rare Neuroimmune Association, and the progress made on rare neuroimmune disorders in the nearly 30 years since its existence.

Episode 37 of the AUPN Leadership Minute features David G. Standaert, MD, PhD, of the University of Alabama at Birmingham; and Erica A. Schuyler, MD, of the University of Connecticut. [WATCH TIME: 5 minutes]

Patients who have 1 of 4 recently identified genetic variants are at 10 times the risk of developing progressive multifocal leukoencephalopathy depending on specific treatments for their condition.

The genetic epidemiologist at the University of Pennsylvania discussed a recent study that highlighted the importance of diverse samples in genetic research for Alzheimer disease in helping to uncover hidden genetic risk factors. [WATCH TIME: 2 minutes]

A recent systematic review showed that AQP4+NMOSD in patients with systemic lupus erythematosus can mimic neuropsychiatric manifestations, frequently occur after the onset of lupus or may predate, and necessitate indefinite treatment.

The combined preclinical and clinical data with neflamapimod suggest the therapy has potential to be the first disease-modifying treatment for dementia with Lewy Bodies, demonstrating a positive impact on cognition, function, and mobility.

Treatment with Nerivio did not differ from controls in outcomes of newborn weight, miscarriage rate, preterm birth rate, birth defect rate, stillbirths, and rate of newborns meeting developmental milestones 3 months postnatal.

The Rett Syndrome Behavior Questionnaire’s implementation as global outcome measure in FDA-approved trials was the result of its comprehensive nature since it includes behavior-related symptom questions as well as questions for regular behaviors.

The professor in the department of internal medicine at RUSH Medical College discussed a study aimed to provide insights to help tailor cognitive decline prevention programs and raise awareness about health disparities in minority populations. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Recent research highlights how advanced technology like remote monitoring devices or wearables and smartphone-based apps for sleep health can be delivered at the point of care to meet the needs of patients.

The assistant professor at Hunter College discussed the importance of using a systematic approach to localization and thorough consideration of clinical symptoms to enhance diagnostic accuracy and reduce misdiagnosis in multiple sclerosis. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke.